Suppr超能文献

胰腺腺癌中HER-2状态的评估:免疫组织化学、定量实时逆转录聚合酶链反应及荧光原位杂交与非整倍体和生存的相关性

Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival.

作者信息

Saxby Alex J, Nielsen Aiqun, Scarlett Christopher J, Clarkson Adele, Morey Adrienne, Gill Anthony, Smith Ross C

机构信息

University of Sydney, Department of Surgery, Royal North Shore Hospital, Australia.

出版信息

Am J Surg Pathol. 2005 Sep;29(9):1125-34. doi: 10.1097/01.pas.0000160979.85457.73.

Abstract

HER-2 is a transmembrane growth factor receptor recognized in overexpression as an independent adverse prognostic factor in several cancers. This study measured HER-2 overexpression in pancreatic adenocarcinoma at the genetic, transcriptional, and translational level. Expression was gauged with regard to stage, grade, and survival. Pancreatic adenocarcinoma samples (n = 30) were analyzed with immunohistochemical labeling for HER-2 protein, Quantitative real-time reverse transcriptase polymerase chain reaction (Q-RT-PCR) measurement of HER-2 mRNA and fluorescence in situ hybridization (FISH) analysis of HER-2 gene expression. HER-2 expression in benign pancreatic lesions (n = 10) provided a control. Five (17%) of the pancreatic adenocarcinomas scored maximal 3+ immunohistochemistry (IHC) labeling, seven (23%) had significantly increased expression of HER-2 mRNA, while only one (3%) exhibited low level HER-2 gene amplification. Ten (33%) tumors demonstrated aneuploidy. In general, concordance between methodologies was poor, but the best agreement was seen between FISH aneuploidy status and Q-RT-PCR mRNA overexpression (80% agreement), followed by IHC and Q-RT-PCR (73% agreement). The least agreement was seen between IHC and FISH aneuploidy status (67% agreement). Tumor stage was positively associated with HER-2 mRNA and protein expression, but tumor grade and other patient characteristics did not reach statistical significance. A poor survival outcome was demonstrated with positive HER-2 status in all three measures of overexpression (Kaplan-Meier log-rank score; P < 0.01 [IHC], P = 0.05 [Q-RT-PCR], P = 0.02 [FISH]). Discordance in expression at the nuclear, cytoplasmic, and cell surface levels highlights the limitations of immunohistochemical evaluation alone and stresses the need for further evaluation of response to anti-HER-2 targeted therapies in tumors displaying overexpression in gene copy, mRNA, and receptor protein.

摘要

HER-2是一种跨膜生长因子受体,在多种癌症中,其过表达被视为一个独立的不良预后因素。本研究在基因、转录和翻译水平上检测胰腺腺癌中HER-2的过表达情况。并根据分期、分级和生存率来评估其表达情况。对30例胰腺腺癌样本进行HER-2蛋白的免疫组化标记分析、HER-2 mRNA的定量实时逆转录聚合酶链反应(Q-RT-PCR)检测以及HER-2基因表达的荧光原位杂交(FISH)分析。选取10例良性胰腺病变样本作为对照。5例(17%)胰腺腺癌免疫组化(IHC)标记评分为最高的3+,7例(23%)HER-2 mRNA表达显著增加,而只有1例(3%)表现出低水平的HER-2基因扩增。10例(33%)肿瘤显示非整倍体。总体而言,各方法之间的一致性较差,但FISH非整倍体状态与Q-RT-PCR mRNA过表达之间的一致性最好(一致性为80%),其次是IHC与Q-RT-PCR(一致性为73%)。IHC与FISH非整倍体状态之间的一致性最差(一致性为67%)。肿瘤分期与HER-2 mRNA和蛋白表达呈正相关,但肿瘤分级和其他患者特征未达到统计学意义。在所有三种过表达检测中,HER-2状态呈阳性均显示出生存结局较差(Kaplan-Meier对数秩检验;P<0.01[IHC],P = 0.05[Q-RT-PCR],P = 0.02[FISH])。核、细胞质和细胞表面水平表达的不一致突出了单纯免疫组化评估的局限性,并强调需要进一步评估在基因拷贝、mRNA和受体蛋白中显示过表达的肿瘤对抗HER-2靶向治疗的反应。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验